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Abstract
Although tyrosyl-DNA phosphodiesterase (TDP1) is capable of removing blocked 3′ termini from
DNA double-strand break ends, it is uncertain whether this activity plays a role in double-strand
break repair. To address this question, affinity-tagged TDP1 was overexpressed in human cells and
purified, and its interactions with end joining proteins were assessed. Ku and DNA-PKcs inhibited
TDP1-mediated processing of 3′-phosphoglycolate double-strand break termini, and in the absence
of ATP, ends sequestered by Ku plus DNA-PKcs were completely refractory to TDP1. Addition of
ATP restored TDP1-mediated end processing, presumably due to DNA-PK-catalyzed
phosphorylation. Mutations in the 2609–2647 Ser/Thr phosphorylation cluster of DNA-PKcs only
modestly affected such processing, suggesting that phosphorylation at other sites was important for
rendering DNA ends accessible to TDP1. In human nuclear extracts, about 30% of PG termini were
removed within a few hours despite very high concentrations of Ku and DNA-PKcs. Most such
removal was blocked by the DNA-PK inhibitor KU-57788, but ~5% of PG termini were removed in
the first few minutes of incubation even in extracts preincubated with inhibitor. The results suggest
that despite an apparent lack of specific recruitment of TDP1 by DNA-PK, TDP1 can gain access to
and can process blocked 3′ termini of double-strand breaks before ends are fully sequestered by DNA-
PK, as well as at a later stage after DNA-PK autophosphorylation. Following cell treatment with
calicheamicin, which specifically induces double-strand breaks with protruding 3′-PG termini,
TDP1-mutant SCAN1 (spinocerebellar ataxia with axonal neuropathy) cells exhibited a much higher
incidence of dicentric chromosomes, as well as higher incidence of chromosome breaks and
micronuclei, than normal cells. This chromosomal hypersensitivity, as well as a small but
reproducible enhancement of calicheamicin cytotoxicity following siRNA-mediated TDP1
knockdown, suggests a role for TDP1 in repair of 3′-PG double-strand breaks in vivo.
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DNA topoisomerase I relaxes DNA supercoiling by forming a transient single-strand break
(SSB) in which Tyr723 of the topoisomerase is covalently linked to the 3′ end of DNA [1].
Tyrosyl-DNA phosphodiesterase (TDP1) is a DNA repair enzyme that cleaves these tyrosyl-
phosphate linkages in the rare instances where the topoisomerase fails to religate the break and
dissociate [2]. Polynucleotide kinase/phosphatase (PNKP) then removes the resulting 3′-
phosphate and phosphorylates the 5′ terminus, and the nick is finally sealed by DNA ligase III
[3]. TDP1 can also process the 3′-phosphoglycolate (3′-PG) moieties often formed during free
radical-mediated DNA cleavage [4], as well as various other 3′ modifications [5], although
much less efficiently than phosphotyrosyl (pTyr) termini. However, at SSBs, 3′-PG moieties
can also be efficiently removed by the apurinic/apyrimidinic endonuclease (APE1) [6], and
thus it is unlikely that PG processing at SSBs would be an essential function of TDP1. In
humans, a missense mutation in TDP1 confers spinocerebellar ataxia with axonal neuropathy
(SCAN1) [7], but it remains to be determined how this specific repair defect leads to SCAN1
symptoms.
Despite its demonstrated interactions with SSB repair proteins [8], TDP1 itself is more active
toward DSB ends than SSB ends [9], and unlike APE1 [10], it can act on protruding 3′ termini
[4]. Moreover, when model DSB substrates bearing protruding 3′-PG termini are incubated in
human whole-cell extracts, a substantial fraction of the PG termini are removed, but there is
no detectable processing of such termini in SCAN1 extracts, suggesting that resolution of
protruding 3′-PG termini is entirely attributable to TDP1, at least in cell extracts [11]. However,
SCAN1 cells are at most only marginally sensitive to ionizing radiation [11], which is expected
to generate many 3′-PG-terminated DSBs [12]. Moreover, direct measurements of DSBs, by
neutral elution and repair focus assays, have failed to detect any significant deficits in repair
of radiation-induced DSBS, in either human SCAN1 cells or Tdp1-/- mouse cells [13,14].
Nevertheless, Tdp-/- mice are sensitive to bleomycin, which induces predominantly blunt-
ended 3′-PG DSBs [15].
To better understand the possible role of TDP1 in end joining, we examined the interplay
between TDP1 and core end joining factors, both as purified proteins and in cell extracts. In
addition, chromosome aberrations were examined following treatment of normal and TDP1-
mutant cells, following treatment with calicheamicin, which specifically induces 3′-PG DSBs.
2. MATERIALS AND METHODS
2.1 Materials
Native DNA-PKcs and Ku were prepared from HeLa cells [16], and recombinant Ku and
XRCC4 / DNA ligase IV complex (X4L4) were isolated from baculovirus-infected insect cells,
as described previously [17]. Mutant DNA-PKcs proteins were purified from DNA-PKcs-
deficient Chinese hamster ovary V3 cells complemented with human DNA-PKcs cDNA [16].
To obtain TDP1 protein, an insert encoding FLAG-tagged TDP1 was isolated from the vector
pFLAG-TDP1 and cloned into the adenoviral vector pZERO-TGCMV. The resulting plasmid
was transfected into Ad293 cells to produce a TDP1-expressing Ad-5(delE1,E3) adenovirus
[18]. The supernatant from these cultures was used to infect subconfluent Ad293 cells (twenty
subconfluent 15-cm dishes) at a multiplicity of 3. After three days, TDP1 protein was isolated
from NP-40 lysates and affinity purified on FLAG beads, essentially as described previously
[11] except that all volumes were increased 4-fold. Because the FLAG peptide used to elute
the tagged protein interfered with chromogenic protein assays, TDP1 concentration was
estimated by comparison with known quantities of BSA on Coomassie-stained polyacrylamide
gels.
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A 3′-pTyr 18-mer with sequence TCCGTTGAAGCCTGCTTT was purchased from Midland
Certified Reagents (Midland, TX). Oligomers bearing 3′-PG termini were prepared by
bleomycin-induced cleavage of partial duplexes, as described [19]. These oligomers were
5′-32P-end-labeled using T4 polynucleotide kinase and [γ-32P]ATP (Perkin-Elmer). To
generate an internally labeled substrate with partially complementary (-ACG/-ACG) 3′-PG
overhangs, one labeled and one unlabeled oligomer were ligated into 10- or 11-base 5′
overhangs of 3′-resected plasmid pRZ56, as described previously [20–22].
The DNA-PK inhibitor KU-57788 (aka NU7441, hereafter designated DNA-PKi) and the
ATM inhibitor KU-55933 (ATMi) were generously provided by Dr. Graeme Smith, KUDOS
Pharmaceuticals. KU-55933 inhibits ATM with an IC50 of 13 nM, vs. 1.8 µM for DNA-PK
[23]. KU-57788 inhibits DNA-PK with an IC50 of 14 nM, vs. >100 µM for ATM [24]. Both
are at least 100-fold more potent in inhibiting their target kinase than any of 60 other kinases
tested [23,24].
2.2 DNA end processing and end-joining reactions
Assays for TDP1 activity toward single-strand 3′-PG and 3′-pTyr oligomers were performed
in 60 mM potassium acetate, 50 mM triethanolammonium acetate pH 7.5, 5 mM EDTA, 1 mM
dithiothreitol and 50 µg/ml BSA. TDP1 was diluted immediately before use in 0.1 M NaCl,
50 mM Tris pH 8, 5 mM EDTA, 5 mM dithiothreitol, 500 µg/ml BSA and 10% glycerol, and
the reactions were incubated for 2 hr at 37°C. In experiments with 3′-PG oligomers, samples
were denatured for 2 min at 90°C and then magnesium acetate (15 mM) and PNKP (40 µg/ml,
gift of Michael Weinfeld, Cross Cancer Institute, Edmonton, Alberta, Canada) were added and
the samples incubated for 1 hr to convert 3′-phosphates generated by TDP1 to 3′-hydroxyls
and thereby increase their electrophoretic separation from 3′-PG substrate [4]. Formamide (1–
2 volumes) was added and the samples were denatured at 90°C for 2 min and subjected to
electrophoresis on 20% polyacrylamide sequencing gels (24% gels for blunt-ended substrates).
End processing reactions with plasmids and purified proteins contained 60 mM potassium
acetate, 50 mM triethanolammonium acetate pH 7.5, 1 mM ATP, 1 mM dithiothreitol, 50 µg/
ml BSA and 5 mM magnesium acetate. Reactions were stopped by dilution into at least 2
volumes of ice-cold 0.45 M sodium acetate / 10 mM EDTA / 100 µg/ml tRNA, followed
immediately by extraction with phenol and then with chloroform at 22°C. Samples were
ethanol-precipitated and treated with AvaI (400 units/ml) for 4 hr at 37°C in 25–50 µl of the
buffer provided by the vendor (New England Biolabs). Calf intestinal phosphatase (120 units/
ml) was added and the samples incubated for an additional 1 hr to remove 3′-phosphates.
Phosphatase also removes the 5′-phosphate but the 32P label is 1 base from the AvaI cleavage
site and is retained. Alternatively, the DNA was treated with phosphatase first and denatured
at 90°C for 5 min, then cut with 400 units/ml TaqαI (New England Biolabs, 65°C, 6 hr), which
cleaves single- as well as double-stranded DNA.
For comparison of reaction rates under various conditions, the extent of reaction was calculated
as -In(fraction of remaining PG termini). Titrations with TDP1 protein and oligomeric
substrates indicated that the extent of reaction was accurately proportional to TDP1
concentration (data not shown).
Reactions with HeLa nuclear extracts contained 3.2 mg/ml extract (Promega in vitro
transcription grade), 50 mM triethanolamine-NaOH pH 7.5, 1 mM Mg(OAc)2, 40 mM KOAc,
0.5 mM dithiothreitol, 1 mM ATP, 50 µM of each dNTP or dideoxynucleoside 5′-triphosphate
(ddNTP), 50 µg/ml BSA, and 1 µg/ml DNA substrate. In some cases X4L4 (5 µg/ml) DNA-
PKi (1 µM) or ATMi (1 µM) were added, as indicated. Following substrate addition, samples
were incubated for the indicated times at 37°C, and deproteinized by treatment with proteinase
K followed by phenol/chloroform extraction. DNA was digested with TaqI (and in some cases
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BstXI to detect end joining), precipitated, and analyzed on polyacrylamide sequencing gels
[21].
2.3 DNase footprinting
To assess accessibility of DNA ends, the same internally labeled 3′-PG substrates were
incubated with Ku, DNA-PKcs and/or ATP as above, and then 1.5 µg/ml DNase I (Sigma) was
added and the samples incubated at 37°C for an additional 10 min. Samples were diluted with
1 volume formamide and denatured for 2 min at 90°C prior to analysis on sequencing gels.
2.4 Cytogenetics
Epstein-Barr virus-transformed lymphoblastoid cells from SCAN1 patients [7] were obtained
from Dr. James Lupski, Baylor College of Medicine, and maintained in RPMI1640 medium
with 10% fetal bovine serum. Calicheamicin (gift of Wyeth Pharmaceuticals) was dissolved
in ethanol and stored at −80°C. It was diluted to 20 µM in DMSO and then diluted in complete
medium just prior to use. Cells were treated with 0–30 pM calicheamicin for 24 hr and then 1
µg/ml colchicine was added 1 hr before harvest. Metaphase spreads were prepared by standard
procedures. For centromere labeling, slides were denatured at 72°C in 70% formamide / 2×SSC
for 2 min and then hybridized to a Cy3-labeled pancentromeric probe (Open Biosystems
#SFP3336) for 16 hr at 37°C, and extensively washed. The highest-stringency wash was with
0.5×SSC at 37°C. Chromosomes were counterstained with DAPI, slides were coded and
metaphases were photographed on a Zeiss LSM510 confocal microscope, using a 405-nm
diode laser with 405-nm blocking and 420-nm long pass emission filters for DAPI, and a 543-
nm helium laser with 543-nm blocking and 560–615-nm bandpass emission filters for Cy3.
Spreads were then scored for acentric fragments and dicentric chromosomes. (See
Supplemental Fig. 4 for further details).
2.5 TDP1 knockdown and clonogenic survival assays
HeLa cells were grown in DMEM plus 10% fetal bovine serum and antibiotics (GIBCO). For
each experiment, 12-well plates were inoculated with 8 × 104 HeLa cells per well and 24 hr
later were transfected with 100 nM TDP1 siRNA (DharmaFECT Smart-Pool) or control
siRNA-A (Santa Cruz biotechnology) using DharmaFECT general transfection protocol
(Dharmacon) with 2.4 µl DharmaFECT Reagent 1 in 0.8 ml medium per well. After 24 hr, the
transfection medium was replaced with complete medium and the incubation was continued
for another 48 hr. The cells were then treated with 6, 20 or 60 pM calicheamicin for 4 hr, plated
at 500 – 20,000 cells per 100-mm dish and incubated at 37°C. After 12 days, cells were fixed
in methanol, stained with crystal violet and colonies were counted. Residual cells not plated
were pooled for each siRNA condition and lysed for determination of TDP1 knockdown. The
cells were pelleted and washed twice with PBS, then lysed on ice with 50 µl of 10 mM HEPES-
KOH pH 7.8, 60 mM KCl, 1 mM EDTA, 0.5% NP-40 plus protease inhibitors (2 µg/ml
aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM NaVO4, 0.5 mM PMSF). Lysates were
cleared by centrifugation (500 × G, 5 min) and TDP1 activity in serial 5:1 dilutions was then
determined from the conversion of the 3′-pTyr oligomer to a 3′-phosphate as described above,
with incubation at 37°C for 2 hr.
3. RESULTS
3.1 Properties of recombinant TDP1 isolated from human cells
Previously, we showed that when a substrate bearing a 3′-PG terminus on a 3′ overhang was
incubated with native Ku purified from human cells, there was significant conversion of the
3′-PG to a 3′-phosphate [4]. This persistent contamination of Ku with TDP1 (which was verified
by western blot) after purification through five columns, raised the possibility that Ku might
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recruit TDP1 to DNA ends and thereby enhance PG processing. However, when recombinant
human Ku purified from baculovirus-infected insect cells was added to reactions containing
recombinant human TDP1 purified from E. coli, the effect of Ku was always inhibitory [4].
Since it is possible that the bacterially produced TDP1 might lack proper folding or post-
translational modifications characteristic of human cells, TDP1 was cloned into an adenovirus,
and FLAG-tagged TDP1 (hereafter designated AdTDP1) was affinity-purified from infected
HEK293 cells using FLAG antibody-conjugated beads (Fig. 1A).
The catalytic properties of recombinant AdTDP1 were similar to those of TDP1 expressed in
E. coli, and in particular the ratio of activity toward 3′-pTyr vs. 3′-PG substrates was about
200:1 (Fig. 1B), similar to the ratio of 80:1 seen with the bacterially produced protein [4]. To
examine the effect of secondary structure on TDP1-mediated end processing, a mixture of
substrates bearing 3′-PG termini on a 6-base 3′ overhang, a blunt end, and a 2-base-recessed
end, was titrated with purified TDP1. The 3′ overhang was processed 3 times more efficiently
than the blunt end and 10 times more efficiently than the recessed end (Fig. 1C), presumably
reflecting differences in accessibility of the termini to TDP1.
3.2 Ku and DNA-PKcs inhibit DNA end processing by TDP1
To assess possible recruitment of AdTDP1 by native Ku, processing of a blunt 3′-PG terminus
was examined. Because this substrate is inherently less susceptible to TDP1 than the 3′
overhang substrate, there was no detectable processing by the small amount of contaminating
TDP1 in native Ku, and so the effect of Ku on PG processing by the recombinant TDP1 could
be accurately assessed. Again, however, the addition of Ku was inhibitory, and the recombinant
and native forms of Ku were equally effective in inhibition (Fig. 2). Thus, despite presence of
TDP1 in preparations of highly purified Ku, it appears unlikely that Ku recruits TDP1 or
stimulates its activity at DSB ends. Addition of recombinant X4L4 complex had either no effect
or a slightly inhibitory effect on TDP1 activity, in either the presence or absence of Ku (data
not shown).
In intact cells, it is likely that free DNA ends would be rapidly sequestered by Ku and DNA-
PKcs, given the abundance of these proteins [25,26]. TDP1-mediated PG processing activity
was therefore examined in the presence or absence of DNA-PKcs, and a substrate bearing a
3′-PG on either a 3-base 3′ overhang (Fig. 3A; quantitated in Fig. 3B–C) or a blunt end (Fig.
3D; quantitated in Fig. 3E). For comparison, binding of DNA ends by Ku and DNA-PKcs
under the same conditions was independently determined by DNase footprinting (Fig. 3F). In
the presence of 50 nM Ku, a concentration that by itself reduced the rate of processing about
twofold (data not shown), DNA-PKcs further inhibited TDP1 activity at DNA ends; in the
absence of ATP, 20 nM DNA-PKcs blocked 3′-PG processing almost completely (Fig. 3C).
Similarly, the same combination of Ku and DNA-PKcs completely protected ~30 bp at the
DNA end from DNase digestion (Fig. 3F). Thus, in the absence of protein phosphorylation,
ends sequestered by Ku and DNA-PKcs are highly resistant if not wholly refractory to TDP1.
3.3 ATP abrogates DNA-PK-mediated inhibition
Biochemical and cellular studies suggest that access to DNA ends is modulated by DNA-PKcs
autophosphorylation, with phosphorylation of the 2609–2647 serine/threonine cluster being
particularly important in promoting accessibility [27]. As expected, addition of ATP to
reactions containing TDP1, Ku and DNA-PKcs partially restored PG processing (closed
symbols in Fig. 3A–E). To replicate conditions used in end joining experiments, 1 mM ATP
was added to these reactions; however, consistent with previous studies of DNA-PKcs release
from DNA ends [28], 10 µM ATP was sufficient to promote end processing. Furthermore, 1
mM ATP did not stimulate TDP1 in the absence of DNA-PK, but instead had a slight inhibitory
effect (Supplemental Fig. 2). Unexpectedly, processing in the presence of ATP was slightly
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greater at 20 nM DNA-PKcs than at 6 nM (Fig. 3E). Because DNA-PK activation by
autophosphorylation requires synapsis of two DNA-PK complexes [29,30], increasing the
DNA-PK concentration could increase the rate of autophosphorylation and thereby promote
greater access to DNA ends. Nevertheless, processing in the presence of Ku plus DNA-PKcs
was always less than in the presence of Ku alone.
It has been proposed that 2609–2647 cluster phosphorylation can render DNA ends accessible
to processing without causing complete DNA-PKcs dissociation [31]. However, in the case of
TDP1, conditions that promoted significant PG processing (i.e., addition of ATP) also resulted
in a measurable increase in susceptibility to DNase I (Fig. 3F). Thus, these data do not
distinguish whether TDP1 could act while phosphorylated DNA-PKcs was still bound to the
DSB ends or could only gain access to 3′ termini when DNA-PKcs dissociated. To more
directly assess the importance of 2609–2647 cluster phosphorylation in promoting TDP1-
mediated end processing, the experiments were repeated with mutant alleles of DNA-PKcs
harboring either S/T→A (unphosphorylatable) or S/T→D (mimicking constitutive
phosphorylation) mutations at all six target sites in the cluster. These mutant proteins retain
full kinase activity [31] and they produced similar footprints upon binding to DNA (Fig. 4A).
In the presence of ATP, reactions with the S/T→A mutant showed a modest reduction in
processing (closed diamonds in Fig. 4B–C), while the S/T→D mutant gave results similar to
wild-type. In the absence of ATP, the S/T→D mutant showed more processing than wild-type
DNA-PKcs, but still much less than was seen in the presence of ATP with any of the DNA-
PKcs proteins (open symbols in Fig. 4). Overall, it appears that phosphorylation of other sites
must be at least as important as phosphorylation of the 2609–2647 cluster, which apparently
promotes processing by TDP1 but is in itself neither necessary nor sufficient.
3.4 Inhibition of DNA-PK blocks most but not all TDP1-mediated end processing in cell
extracts
When model DSB substrates bearing protruding 3′-PG termini are incubated in human whole-
cell extracts, a substantial fraction of the termini are converted to 3′-hydroxyls [4]. The absence
of such conversion in SCAN1 extracts [11] and in Tdp1-/- mouse fibroblast extracts [32]
strongly suggests that this reaction is catalyzed by TDP1 and PNKP. When the same substrate
was incubated in HeLa nuclear extracts, a small fraction (~5%) of PG termini were removed
within 5 min (Fig. 5A–C). PG removal continued for several hours, but at a steadily decreasing
rate, so that even after 5 hr, ~70% of PG ends remained intact (closed circles in Fig. 5C). This
decrease in the rate of processing did not appear to be due to loss of TDP1 activity over time,
as a substrate added to extract that had been preincubated for 2 hr was likewise subject to an
initial burst of rapid processing (open inverted triangles in Fig. 5C). Moreover, when a single-
stranded 3′-PG substrate was incubated in the same diluted extracts, most of the glycolate was
removed within 20 min and the reaction proceeded to completion by 2 hr even at an eightfold
lower concentration (0.4 mg/ml) of extract (Fig. 5F). These results suggest that TDP1 in HeLa
extracts is sufficiently abundant and stable to effect complete processing of exposed 3′-PG
termini, and that the failure to completely process 3′ overhangs is due to protection of these
ends by other cellular components.
To determine whether the levels of Ku and DNA-PKcs in HeLa nuclear extracts would be
sufficient to block TDP1-mediated processing, Western blots were performed with various
quantities of nuclear extract and of purified recombinant Ku and DNA-PKcs (Supplemental
Fig. 3). These titrations indicated that HeLa extracts contained 560 ± 90 nM DNA-PKcs and
4.1 ± 1.4 µM Ku, which would result in concentrations of approximately 110 nM DNA-PKcs
and 820 nM Ku in end joining reactions. Judging from the in vitro studies (Fig. 3), in the
absence of DNA-PKcs phosphorylation, these concentrations would be more than adequate to
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block all processing. To test this prediction, reactions were performed in extracts containing
the DNA-PK inhibitor KU-57788 (DNA-PKi).
When added 10 min before the substrate, DNA-PKi had little if any effect on PG removal in
the first 5 min, but processing at later times was blocked completely (Fig. 5B, 5C and 5E). In
the absence of inhibitor, there was also a detectable level of end joining, as indicated by the
formation of diagnostic 42- and 24-base fragments (Fig. 5A), and this joining was also
completely blocked by DNA-PKi, as expected (Fig. 5A, 5D and 5E). It has been reported that
in intact cells, most if not all DNA-PKcs phosphorylation in the 2609–2647 cluster is catalyzed
by ATM rather than DNA-PK itself [33]. However, an ATM inhibitor (ATMi) did not prevent
end joining (Fig. 5A). Moreover, it did not inhibit processing of PG ends; if anything, ATMi
appeared to slightly stimulate PG removal during the first 5 min (Fig. 5E). Overall, the results
suggest that, when its catalytic activity is blocked, DNA-PK forms a complex on DNA ends
that completely protects the ends from processing by TDP1. Thus, the rapid, DNA-PKi-
resistant processing in the first 5 min probably occurred before the repair complex had fully
formed on the DNA end.
3.5 TDP1-mutant SCAN1 cells show chromosomal hypersensitivity to calicheamicin
Calicheamicin is a natural product which upon activation forms a diradical species that
simultaneously attacks both strands of DNA on a 3-base 3′ stagger [34]. One end of each
calicheamicin-induced DSB has a 5′-phosphate, and 3-base 3′ overhang with a 3′-phosphate.
The opposite DSB end has a 5′ aldehyde and a 2-base 3′ overhang with either a 3′-phosphate
or a 3′-PG (Fig. 6A). Thus, the calicheamicin-induced DSBs that bear 3′-PG termini are similar
to the synthetic substrates that require TDP1 for processing in cell extracts.
To determine the possible role of TDP1 in repair of these DSBs in intact cells, TDP1-mutant
SCAN1 lymphoblastoid cells were treated with calicheamicin, and then assayed for formation
of micronuclei (Fig. 6B). Consistently, either with or without 1 mM caffeine (to minimize G2
arrest), the fraction of cells containing micronuclei was about 1.5-fold higher for SCAN1 cells
than for identically treated normal cells derived from unaffected relatives. Similarly, levels of
acentric chromosome fragments as measured on metaphase spreads with fluorescent-stained
centromeres, were ~1.5-fold higher for SCAN1 cells than for normal cells (Fig. 6C). 4).
Furthermore, numbers of dicentric chromosomes were much greater in SCAN1 than in normal
cells, and there was a particularly dramatic increase in the number of cells having more than
one dicentric (Fig. 6D). Elevated levels of calicheamicin-induced dicentric chromosomes were
detected consistently in two other SCAN1 lines as well (Supplemental Fig. 5). These results
suggest that calicheamicin-induced DSBs were repaired less accurately and perhaps less
efficiently or more slowly in SCAN1 than in normal cells. However, there was little if any
chromosomal hypersensitivity to ionizing radiation (Supplemental Fig. 6).
3.6 Knockdown of TDP1 by siRNA in HeLa cells confers calicheamicin sensitivity
Attempts to assess calicheamicin cytotoxicity toward SCAN1 cells by a cytometry-based
growth assay [35] yielded inconclusive results; although calicheamicin hypersensitivity was
seen in some experiments, there was variability among individual cell lines that was
comparable to differences between normal and SCAN1 lines (data not shown). Therefore,
clonogenic survival assays were performed on HeLa cells following knockdown of TDP1 with
a pool of four siRNAs (Fig. 7). Assays based on removal of tyrosine from a 3′-pTyr 18-mer
indicated an 8-fold reduction in TDP1 activity in extracts of the siRNA-treated cells, compared
to an unrelated control siRNA (Fig. 7A). TDP1 knockdown was associated with a small but
reproducible increase in cytotoxicity, with a 1.25-fold increase in log cell kill at 60 pM
calicheamicin (Fig. 7B).
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Previous work showed that TDP1-mutant SCAN1 cells, as well as extracts from these cells,
are deficient in the rejoining of SSBs induced by topoI inhibitors [14,36], clearly implicating
TDP1 in repair of topoI-mediated breaks. Moreover, TDP1 binds directly to DNA ligase III,
the primary ligase in the SSB repair pathway [36]. In vitro, TDP1 can also resolve 3′-PG
termini, which are typical of free radical-mediated DNA breaks, and extracts of SCAN1 cells
as well as Tdp1-/- murine fibroblasts are completely deficient in processing of protruding 3′-
PG termini at DNA DSB ends [11,32]. While these results suggest a possible role for TDP1
in resolving 3′ blocks at DSB termini, direct assays for repair of radiation-induced DSBs in
intact cells did not reveal any apparent DSB repair defect in either SCAN1 cells or Tdp1-/-
mouse fibroblasts [13,14]. However, interpretation of these data is complicated by the fact that
the frequency of 3′-PG termini at these DSB ends is uncertain. Although early studies suggested
that about half of radiation-induced DNA breaks had 3′-PG termini [12], a more recent estimate
by mass spectrometry yielded a much lower estimate of ~10% [37]. If this latter value is correct,
then a 3′-PG processing defect might not confer either significant radiosensitivity or a
noticeable defect in DSB rejoining.
To further assess the possible role of TDP1 in repair of DSBs with blocked 3′ termini, we
examined the interplay between TDP1 and the core NHEJ component DNA-PK, at DNA ends.
Given the high levels of Ku and DNA-PKcs in human cells [25], it is highly likely that free
DNA ends, regardless of their source, would rapidly recruit both Ku and DNA-PKcs. Thus,
any putative end processing by TDP1 would take place in the context of ends sequestered by
DNA-PK.
Experiments with purified proteins suggest that when Ku and unphosphorylated DNA-PKcs
are bound to a DNA end bearing a PG on a short 3′ overhang, the PG is completely protected
from TDP1-mediated glycolate removal (Fig. 3). Moreover, whereas phosphorylation of the
2609–2647 serine/threonine cluster in DNA-PKcs has been proposed to induce a
conformational change that promotes end accessibility [31], S/T→D mutations that mimic such
phosphorylation increased 3′-PG processing in the absence of ATP only very slightly. This
result is somewhat at odds with a previous finding that the same S/T→D DNA-PKcs mutant
allowed digestion of DNA ends by exonuclease V in the absence of ATP, under conditions
where the wild-type enzyme protected the ends almost completely when phosphorylation was
blocked by wortmannin [31]. This disparity may reflect differences in the details of binding of
the individual enzymes to DNA, for example the proposed requirement that DNA become at
least transiently single-stranded in order to properly bind to TDP1 [28]. Nevertheless, addition
of ATP strongly promoted 3′-PG processing, suggesting that DNA-PK-mediated
phosphorylation, of either itself or other proteins, does make ends more accessible. In whole-
cell extracts, the S/T→A mutant form of DNA-PK still supports some end processing and gap
filling, while both these processes are blocked completely by DNA-PKi, even in the presence
of the S/T→D mutant. These results, like those reported above, suggest that there are other
DNA-PK-catalyzed phosphorylations that are at least as important as the 2609–2647 cluster
in promoting end accessibility and processing. However, none of these data distinguish whether
this accessibility reflects dissociation of DNA-PKcs from some ends, or only a conformational
change in DNA-PKcs that still remains bound.
In an attempt to distinguish between these alternatives, DNase footprinting was performed. If
DNA-PKcs underwent a major conformational change without dissociation, a qualitatively
different footprint might result. Instead, the DNase cleavage pattern seen after incubation in
the presence of ATP was weaker but otherwise similar to that seen in the absence of DNA-PK
(Fig. 3F), consistent with the view that a fraction of the DNA ends was free of any DNA-PK
while the rest remained fully sequestered. There are at least 12 potential sites of
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autophosphorylation on DNA-PKcs, and extensive autophosphorylation of DNA end-bound
DNA-PKcs can result in complete dissociation from the DNA [38]. Since in our experiments
DNA-PKcs is present in at least a 10-fold excess with respect to DNA ends, it is expected that
any such dissociated, phosphorylated DNA-PKcs would be replaced by a fresh
unphosphorylated molecule. If reloading of DNA-PKcs onto the DNA end were sufficiently
rapid, then there would be little or no processing until the entire pool of unphosphorylated
DNA-PKcs was exhausted, at which point the rate of PG processing would abruptly increase.
On the contrary, however, PG processing in the presence of DNA-PK and ATP appeared to
proceed linearly from time zero (Fig. 3B and 3E), consistent with a model [39] in which each
DNA-PKcs dissociation is followed by an interval when the DNA end is relatively accessible
to TDP1, before the end is again sequestered by a new molecule of DNA-PKcs.
A similar situation appears to prevail in nuclear extracts (Fig. 5), where PG removal likewise
proceeds continuously from time zero despite high concentrations of DNA-PKcs (~0.1 µM)
and Ku (~0.8 µM). The fact that there is significant PG removal in the first 5 min even when
DNA-PK kinase activity is blocked, also suggests that end sequestration by DNA-PKcs is not
immediate and that there is opportunity for end processing before the end-bound repair complex
is fully formed. Moreover, the experiments with cell extracts indicate that such processing can
occur in the presence of not only DNA-PK, but of all proteins required for efficient NHEJ.
In intact cells, the chromosomal sensitivity of SCAN1 cells to calicheamicin provides
additional evidence of a role for TDP1 in DSB repair. The calicheamicin-induced DSB is
unique in that one end of the break often bears a 3′-PG and a 5′-aldehyde [34,40]; thus, at least
one of these blocking groups must be removed in order for end joining to proceed. Most free
radical-mediated DSBs resulting from deoxyribose oxidation at positions other than C-4′ will
bear 5′-phosphate and 3′-phosphate termini [41,42], and the latter can be readily converted to
3′-hydroxyls by PNKP, which binds to the core NHEJ protein XRCC4. Thus, the vast majority
of DSBs induced by diffusible free radicals could presumably be rejoined in at least one strand
without any additional enzymes for removal of modified ends. The presence of abnormal
termini in both strands at one end of the calicheamicin-induced DSB may explain, in part, the
extraordinary cytotoxicity of this compound, as well as the apparent requirement for TDP1 for
optimal repair. These doubly blocked ends are likely to be resistant to many of the 3′→5′ and
5′→3′ exonucleases that otherwise might initiate resection-based end joining [43]. Their
resolution may instead require either a specific end-processing enzyme such as TDP1, or an
endonucleolytic cleavage near the terminus, perhaps preceded by limited helicase-mediated
unwinding of the terminal base pairs.
Thus, taken together, the results suggest that despite lack of demonstrable specific interactions
with core NHEJ proteins, TDP1 can participate in resolution of blocked 3′ DSB termini in the
context of NHEJ. Although Artemis nuclease plus DNA-PK can also process blocked termini
on 3′ overhangs, this processing is slow and inefficient for very short overhangs [35]. Therefore,
in SCAN1 cells, 3′-PG-terminated DSBs may tend to persist longer than in normal cells,
potentially increasing the probability that they will be incorrectly joined. The very small
enhancement of calicheamicin cytotoxicity seen in TDP1-knockdown cells, as well as the
finding that in SCAN1 cells calicheamicin-induced dicentrics are enhanced more than
chromosome breaks, suggest that TDP1 deficiency confers a marked increase in misrepair but
perhaps only a slight defect in the extent of overall rejoining.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Zhou et al. Page 9














We thank Graeme Smith and KUDOS Pharmaceuticals for providing KU-57788 and KU-55933, Wyeth
Pharmaceuticals for supplying calicheamicin, Michael Weinfeld for supplying PNKP and Sarah Elsea (Dept. of Human
Genetics) for advice on cytogenetics. This work was supported by Grants AG023783 and CA40615 from the National
Institutes of Health, USDHHS. Confocal microscopy was supported in part by Grant P30 CA16059 to the Massey
Cancer Center.
REFERENCES
1. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res 2001;80:189–
216. [PubMed: 11034544]
2. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the
phospholipase D superfamily. Proc. Natl. Acad. Sci. U. S. A 2001;98:12009–12014. [PubMed:
11572945]
3. Caldecott KW. DNA single-strand break repair and spinocerebellar ataxia. Cell 2003;112:7–10.
[PubMed: 12526788]
4. Inamdar KV, Pouliot JJ, Zhou T, Lees-Miller SP, Rasouli-Nia A, Povirk LF. Conversion of
phosphoglycolate to phosphate termini on 3′ overhangs of DNA double-strand breaks by the human
tyrosyl-DNA phosphodiesterase hTdp1. J. Biol. Chem 2002;276:24323–24330. [PubMed: 11309379]
5. Interthal H, Chen HJ, Champoux JJ. Human Tdp1 cleaves a broad spectrum of substrates, including
phosphoamide linkages. J. Biol. Chem 2005;280:36518–36528. [PubMed: 16141202]
6. Wilson DM. Properties of and substrate determinants for the exonuclease activity of human apurinic
endonuclease Ape1. J. Mol. Biol 2003;330:1027–1037. [PubMed: 12860125]
7. Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, Armstrong D, Mao Y, Quiocho FA, Roa BB,
Nakagawa M, Stockton DW, Lupski JR. Mutation of TDP1, encoding a topoisomerase I-dependent
DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat. Genet
2002;32:267–272. [PubMed: 12244316]
8. Plo I, Liao ZY, Barcelo JM, Kohlhagen G, Caldecott KW, Weinfeld M, Pommier Y. Association of
XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA
lesions. DNA Repair 2003;2:1087–1100. [PubMed: 13679147]
9. Raymond AC, Staker BL, Burgin AB Jr. Substrate specificity of tyrosyl-DNA phosphodiesterase I
(Tdp1). J. Biol. Chem 2005;280:22029–22035. [PubMed: 15811850]
10. Suh D, Wilson DM III, Povirk LF. 3′-Phosphodiesterase activity of human apurinic/apyrimidinic
endonuclease at DNA double-strand break ends. Nucleic Acids Res 1997;25:2495–2500. [PubMed:
9171104]
11. Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, Povirk LF. Deficiency in 3′-phosphoglycolate
processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1).
Nucleic Acids Res 2005;33:289–297. [PubMed: 15647511]
12. Henner WD, Rodriguez LO, Hecht SM, Haseltine WA. gamma-Ray induced deoxyribonucleic acid
strand breaks. 3′ glycolate termini. J. Biol. Chem 1983;258:711–713. [PubMed: 6822504]
13. El-Khamisy SF, Hartsuiker E, Caldecott KW. TDP1 facilitates repair of ionizing radiation-induced
DNA single-strand breaks. DNA Repair 2007;6:1485–1495. [PubMed: 17600775]
14. Katyal S, El-Khamisy SF, Russell HR, Li Y, Ju L, Caldecott KW, McKinnon PJ. TDP1 facilitates
chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J
2007;26:4720–4731. [PubMed: 17914460]
15. Hirano R, Interthal H, Huang C, Nakamura T, Deguchi K, Choi K, Bhattacharjee MB, Arimura K,
Umehara F, Izumo S, Northrop JL, Salih MA, Inoue K, Armstrong DL, Champoux JJ, Takashima
H, Boerkoel CF. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive
neomorphic mutation? EMBO J 2007;26:4732–4743. [PubMed: 17948061]
16. Goodarzi AA, Lees-Miller SP. Biochemical characterization of the ataxia-telangiectasia mutated
(ATM) protein from human cells. DNA Repair 2004;3:753–767. [PubMed: 15177184]
17. Nick McElhinny SA, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4-ligase IV
complex to DNA ends. Mol. Cell. Biol 2000;20:2996–3003. [PubMed: 10757784]
Zhou et al. Page 10













18. Holmes M, Rosenberg E, Valerie K. Adenovirus expressing p53. Methods Mol. Biol 2003;234:1–16.
[PubMed: 12824521]
19. Chen S, Hannis JC, Flora JW, Muddiman DC, Charles K, Yu Y, Povirk LF. Homogeneous
preparations of 3′-phosphoglycolate-terminated oligodeoxynucleotides from bleomycin-treated
DNA as verified by electrospray ionization Fourier transform ion cyclotron resonance mass
spectrometry. Anal. Biochem 2001;289:274–280. [PubMed: 11161322]
20. Bennett RAO, Gu X-Y, Povirk LF. Construction of a vector containing a site-specific DNA double-
strand break with 3′-phosphoglycolate termini and analysis of the products of end-joining in CV-1
cells. Intl. J. Radiat. Biol 1996;70:623–636. [PubMed: 8980659]
21. Chen S, Inamdar KV, Pfeiffer P, Feldmann E, Hannah MF, Yu Y, Lee JW, Zhou T, Lees-Miller SP,
Povirk LF. Accurate in vitro end-joining of a DNA double-strand break with partially cohesive 3′-
overhangs and 3′-phosphoglycolate termini: Effect of Ku on repair fidelity. J. Biol. Chem
2001;276:24323–24330. [PubMed: 11309379]
22. Povirk LF, Zhou RZ, Ramsden DA, Lees-Miller SP, Valerie K. Phosphorylation in the serine/
threonine 2609–2647 cluster promotes but is not essential for DNA-dependent protein kinase-
mediated nonhomologous end joining in human whole-cell extracts. Nucleic Acids Res 2007;5:3869–
3878. [PubMed: 17526517]
23. Hollick JJ, Rigoreau LJ, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard
S, Hardcastle IR, Hickson I, Hummersone MG, Menear KA, Martin NM, Matthews I, Newell DR,
Ord R, Richardson CJ, Smith GC, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of
phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent
protein kinase and inhibition, and identification of the first potent and selective inhibitor of the ataxia
telangiectasia mutated kinase. J. Med. Chem 2007;50:1958–1972. [PubMed: 17371003]
24. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, Stockley M, Golding BT, Rigoreau
L, Richardson C, Smith GC, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-
dependent protein kinase (DNA-PK) using a small-molecule library approach. J. Med. Chem
2005;48:7829–7846. [PubMed: 16302822]
25. Anderson CW, Lees-Miller SP. The nuclear serine/threonine protein kinase DNA-PK. Crit. Rev.
Eukaryotic Gene Expression 1992;2:283–314.
26. Chan DW, Mody CH, Ting NS, Lees-Miller SP. Purification and characterization of the double-
stranded DNA-activated protein kinase, DNA-PK, from human placenta. Biochem. Cell Biol
1996;74:67–73. [PubMed: 9035691]
27. Meek K, Gupta S, Ramsden DA, Lees-Miller SP. The DNA-dependent protein kinase: the director
at the end. Immunol. Rev 2004;200:132–141. [PubMed: 15242401]
28. Davies DR, Interthal H, Champoux JJ, Hol WG. The crystal structure of human tyrosyl-DNA
phosphodiesterase, Tdp1. Structure (Camb) 2002;10:237–248. [PubMed: 11839309]
29. DeFazio LG, Stansel RM, Griffith JD, Chu G. Synapsis of DNA ends by DNA-dependent protein
kinase. EMBO J 2002;21:3192–3200. [PubMed: 12065431]
30. Weterings E, Verkaik NS, Bruggenwirth HT, Hoeijmakers JH, van Gent DC. The role of DNA
dependent protein kinase in synapsis of DNA ends. Nucleic Acids Res 2003;31:7238–7246.
[PubMed: 14654699]
31. Reddy YV, Ding Q, Lees-Miller SP, Meek K, Ramsden DA. Non-homologous end joining requires
that the DNA-PK complex undergo an autophosphorylation-dependent rearrangement at DNA ends.
J. Biol. Chem 2004;279:39408–39413. [PubMed: 15258142]
32. Hawkins AJ, Subler MA, Akopiants K, Wiley JL, Taylor SM, Rice AC, Windle JJ, Valerie K, Povirk
LF. In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from
tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair. 2009in
press.
33. Chen BP, Uematsu N, Kobayashi J, Lerenthal Y, Yajima H, Löbrich M, Chen DJ. ATM is essential
for DNA-PKcs phosphorylations at T2609 cluster upon DNA double-strand break. J. Biol. Chem
2007;282:6582–6587. [PubMed: 17189255]
34. Dedon PC, Goldberg IH. Free-radical mechanisms involved in the formation of sequence-dependent
bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin.
Chem. Res. Toxicol 1992;5:311–332. [PubMed: 1380322]
Zhou et al. Page 11













35. Povirk LF, Zhou T, Zhou R, Cowan MJ, Yannone SM. Processing of 3′-phosphoglycolate-terminated
DNA double strand breaks by Artemis nuclease. J. Biol. Chem 2007;282:3547–3558. [PubMed:
17121861]
36. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR, Caldecott KW.
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature
2005;434:108–113. [PubMed: 15744309]
37. Chen B, Zhou X, Taghizadeh K, Chen J, Stubbe J, Dedon PC. GC/MS methods to quantify the 2-
deoxypentos-4-ulose and 3′-phosphoglycolate pathways of 4′ oxidation of 2-deoxyribose in DNA:
application to DNA damage produced by gamma radiation and bleomycin. Chem. Res. Toxicol
2007;20:1701–1708. [PubMed: 17944541]
38. Chan DW, Lees-Miller SP. The DNA-dependent protein kinase is inactivated by autophosphorylation
of the catalytic subunit. J. Biol. Chem 1996;271:8936–8941. [PubMed: 8621537]
39. Calsou P, Frit P, Humbert O, Muller C, Chen DJ, Salles B. The DNA-dependent protein kinase
catalytic activity regulates DNA end processing by means of Ku entry into DNA. J. Biol. Chem
1999;274:7848–7856. [PubMed: 10075677]
40. Povirk LF. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin
neocarzinostatin and other enediynes. Mutat. Res 1996;355:71–89. [PubMed: 8781578]
41. Hutchinson F. Chemical changes induced in DNA by ionizing radiation. Prog. Nucleic Acids Res.
Mol. Biol 1985;32:115–154.
42. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms
of formation, and reparability. Prog. Nucleic Acid. Res. Mol. Biol 1988;35:95–125. [PubMed:
3065826]
43. Harrigan JA, Fan J, Momand J, Perrino FW, Bohr VA, Wilson DM. WRN exonuclease activity is
blocked by DNA termini harboring 3′ obstructive groups. Mech. Ageing Dev 2007;128:259–266.
[PubMed: 17224176]
Zhou et al. Page 12














Characterization of recombinant AdTDP1 isolated from human cells. A. Silver-stained SDS /
10% polyacrylamide gel showing affinity purification of AdTDP1 on FLAG beads. Samples
include the initial lysate (5 µl), the supernatant following pelleting of the beads (10 µl), the
beads pelleted after elution of protein with FLAG peptide (5 µl), and the eluted protein (10 µl).
B. A mixture of a 3′-pTyr 18-mer (▼) and a 3′-PG 14-mer (●) (20 nM each) was titrated with
various dilutions of AdTDP1, and processing was assessed by gel electrophoresis
(Supplemental Fig. 1), as described in the Methods. C. A mixture of plasmid substrates bearing
3′-PG termini on a 5-base 3′ overhang (◆), a blunt end (○) or a 2-base 3′-recessed end (●) was
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titrated with AdTDP1. See Supplemental Fig. 1 and ref. [35] for a detailed description of these
substrates. Incubations were for 2 hr at 37°C, and all samples were subsequently treated with
PNKP to convert TDP1-induced 3′-phosphate to 3′-hydroxyl termini.
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Inhibition of TDP1-mediated 3′-PG processing by Ku. A. A plasmid bearing a 3′-PG on a 3-
base 3′ overhang (see Fig. 3A) was treated with 30 nM AdTDP1 for the indicated times at 37°
C in the presence of 0 (●), 50 (○) or 150 nM (▼) native human Ku, and glycolate removal was
assessed as described in the METHODS. B. TDP1-mediated glycolate removal was assessed
following treatment for the indicated times without Ku (●) or in the presence of 50 nM
recombinant Ku (▼) or native Ku (○). C. Gel from which the data in (B.) were derived.
Following deproteinization, the samples were treated with AvaI to release a labeled 15-mer
from the end of the plasmid, and then with calf intestinal phosphatase to remove the 3′-
phosphate.
Zhou et al. Page 15














Inhibition of TDP1-mediated 3′-PG processing by DNA-PK in the presence or absence of ATP.
All samples also contained 50 nM recombinant Ku and incubation was for 20 or 80 min at 37°
C in the presence (closed symbols) or absence (open symbols) of ATP. DNA-PKcs
concentration in (B.) and (D.) was 0 (▼), 6 (●,○) or 20 nM (■,□). Substrates were a plasmid
bearing 3′-PG termini on either a 3-base 3′ overhang as shown (A., quantitated in B. and C.,
treatment with 8 nM TDP1) or an otherwise identical substrate with a 3′-PG blunt end (D.,
quantitated in E., treatment with 37 nM TDP1). Panel (C.) shows pooled data (mean ± SEM)
from 3 experiments with the 3′ overhang, with incubation in the presence or in the absence of
ATP; the extent of processing for each sample after 80 min incubation was determined and
then normalized to that for the sample containing Ku but no DNA-PKcs. In parallel, the 3′-
Zhou et al. Page 16













overhang substrate was incubated for 20 min in the presence of Ku, with or without 20 nM
DNA-PKcs and/or 1 mM ATP as indicated, and then subjected to DNase footprinting (F.). A
replicate footprinting experiment (not shown) gave essentially the same result.
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Effect of mutations in the 2609–2647 serine/threonine cluster of DNA-PKcs on PG processing.
A. The substrate shown was incubated in the absence of ATP for 10 min with 50 nM Ku and
20 nM either wild-type DNA-PKcs or DNA-PKcs having six S/T→A or six S/T→D mutations
in the 2609–2647 cluster, then subjected to DNase footprinting. B. The same substrate was
incubated with 50 nM Ku and 8 nM TDP1, in the presence (closed symbols) or absence (open
symbols) of ATP, with either no DNA-PKcs (△), or 20 nM DNA-PKcs, either wild-type (●,○),
or having the same six S/T→A (◆,◊) or S/T→D (▼,▿) mutations. PG processing was analyzed
as in Fig. 3. B. Compilation of data from three replicate experiments. Symbols are the same as
in (B.). The extent of processing under each condition has been normalized to that seen with
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wild-type DNA-PKcs in the presence of ATP. The mutated residues in DNA-PKcs are T2609,
S2612, T2620, S2624, T2638 and T2647.
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Effect of kinase inhibitors on processing of 3′-PG ends in HeLa extracts. A. The substrate
shown, bearing PG termini on 3-base 3′ overhangs, was incubated in HeLa nuclear extracts
(3.2 mg/ml) for 5 min or 5 hr, with or without DNA-PKi, ATMi and exogenous recombinant
X4L4 as indicated. The 14-base fragment represents the free 3′-hydroxyl derived from removal
of 3′-PG by TDP1 and PNKP. The 24-base fragment represents intermolecular head-to-head
joining, by the same mechanism shown for head-to-tail joining. The top portion of the gel is
shown at tenfold higher contrast to visualize end-joining bands. B.-D. Quantitation of data
from an experiment similar to that shown in A., with incubations in the presence of DNA-PKi
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(▼), its solvent (DMSO) alone (○) or no addition (●). In a fourth sample (▿), the substrate was
added after pre-incubation of the extract for 2 hr. The amount of each species is expressed as
a fraction of the total radioactivity in the lane, excluding a small fraction that remained in the
well. End joining (D.) is the sum of the 42- and 24-base products. E. Compilation of PG removal
data from three such experiments, showing mean + SEM. F. Processing of 3′-PG termini on a
single-strand 14-mer by various dilutions of HeLa extract, in the presence of 5 mM EDTA;
samples were then denatured and treated with PNKP to remove 3′-phosphates.
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Chromosomal sensitivity of SCAN1 cells to calicheamicin. A. Structure of calicheamicin-
induced DSBs. B. SCAN1 (#1664) or normal (#1668) cells were treated with the indicated
concentrations of calicheamicin and then stained with DAPI, and the fraction of cells with
micronuclei was determined. Approximately 100 cells were scored in each of three independent
experiments (mean ± SEM). C. Following calicheamicin treatment, metaphase cells were
collected for 1 hr with colchicine, and then metaphase spreads were prepared and hybridized
with a fluorescent (Cy3) centromeric probe (typical metaphase shown in Supplemental Fig.
4). Approximately 50 metaphases were photographed and scored for acentric fragments and
dicentric chromosomes, and the number of each type of aberration per cell was calculated. D.
Same data as (C.), but expressed as the fraction of cells having at least one, or more than one
aberration of each type. The mitotic index was between 2% and 4% for all samples.
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Effect of TDP1 knockdown on calicheamicin cytotoxicity toward HeLa cells. Cells were
transfected with TDP1 siRNA (●), control siRNA (○) or transection reagent alone (▼) for 24
hr, incubated for 48 hr, treated for 4 hr with calicheamicin and then either lysed for
determination of TDP1 activity (A), or plated for determination of clonogenic survival (B).
Error bars represent the SEM for three survival determinations from two independent
experiments. TDP1 activity titrations indicated a 7.9-fold decrease following TDP1
knockdown; a second independent experiment indicated an 8.0-fold decrease (not shown).
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